Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands

被引:16
作者
Freudenburg-de Graaf, W. [1 ,2 ]
Knol, M. J. [3 ]
van der Ende, A. [1 ,2 ]
机构
[1] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Netherlands Reference Lab Bacterial Meningitis, Amsterdam, Netherlands
[3] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, Bilthoven, Netherlands
基金
英国惠康基金;
关键词
Neisseria meningitidis; 4CMenB vaccine; Whole-genome sequencing; gMATS; B VACCINE; BACTERICIDAL ANTIBODIES; PERSISTENCE; AGE; IMMUNOGENICITY; IMMUNIZATION; ADOLESCENTS; INFANTS; STRAIN;
D O I
10.1016/j.vaccine.2020.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Neisseria meningitidis serogroup B is a major cause of invasive meningococcal disease in Europe. In the absence of a conjugate serogroup B vaccine, a subcapsular 4CMenB vaccine was developed. Data on 4CMenB vaccine efficacy is still limited. Recently, genomic MATS (Meningococcal Antigen Typing System) was developed as a tool to predict strain coverage, using vaccine antigens sequence data. We characterized all invasive meningococcal isolates received by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) in two epidemiological years 2017-2019 using whole-genome sequencing and determined serogroup, clonal complex (cc) and estimated 4CMenB vaccine coverage by gMATS. Of 396 cases of invasive meningococcal disease, corresponding to an incidence of 1.22 cases/10(5) inhabitants, 180 (45%) were serogroup W, 155 (39%) serogroup B, 46 (12%) serogroup Y, 10 (3%) serogroup C, 2 non-groupable (0.5%) and 3 (0.7%) unknown. The incidence was the highest among 0-4 years olds (4 cases/10(5) inhabitants), and 57/72 (79%) of these cases were serogroup B. Serogroup W predominated among persons 45 years of age or older with 110/187 (59%) cases. Serogroup B isolates comprised 11 different clonal complexes, with 103/122 (84%) isolates belonging to 4 clonal complexes: cc32, cc41/44, cc269 and cc213. In contrast, serogroup W isolates were genetically similar with 95% belonging to ccl 1. Of 122 serogroup B isolates, 89 (73%; 95% CI: 64-80%) were estimated to be covered by 4CMenB and the degree of coverage varied largely by clonal complex and age. Among the 0-4 year olds, 25 of 43 (58%; 95% CI: 43-72%) MenB isolates were estimated to be covered. Since the coverage of the 4CMenB vaccine is dependent on circulating clonal complexes, our findings emphasize the need for surveillance of circulating meningococcal strains. In addition, estimation of age specific coverage is relevant to determine the right target age group for vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:7850 / 7857
页数:8
相关论文
共 50 条
[41]   Molecular characterization of invasive Neisseria meningitidis isolates collected in Lithuania (2009-2019) and estimation of serogroup B meningococcal vaccine 4CMenB and MenB-Fhbp coverage [J].
Sereikaite, Emilija ;
Plepyte, Ruta ;
Petrutiene, Aurelija ;
Stravinskiene, Dovile ;
Kucinskaite-Kodze, Indre ;
Gegzna, Vilmantas ;
Ivaskeviciene, Inga ;
Zvirbliene, Aurelija ;
Pleckaityte, Milda .
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2023, 13
[42]   Impact of Meningococcal B (4CMenB) Vaccine on Pharyngeal Neisseria meningitidis Carriage Density and Persistence in Adolescents [J].
McMillan, Mark ;
Walters, Luke ;
Sullivan, Thomas ;
Leong, Lex E. X. ;
Turra, Mark ;
Lawrence, Andrew ;
Koehler, Ann P. ;
Finn, Adam ;
Andrews, Ross M. ;
Marshall, Helen S. .
CLINICAL INFECTIOUS DISEASES, 2021, 73 (01) :E99-E106
[43]   Reassuring safety data from the UK multicomponent meningococcal group B vaccine (4CMenB) programme [J].
Bettinger, Julie A. .
LANCET CHILD & ADOLESCENT HEALTH, 2018, 2 (06) :380-381
[44]   Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination [J].
Martinon-Torres, Federico ;
Banzhoff, Angelika ;
Azzari, Chiara ;
De Wals, Philippe ;
Marlow, Robin ;
Marshall, Helen ;
Pizza, Mariagrazia ;
Rappuoli, Rino ;
Bekkat-Berkani, Rafik .
JOURNAL OF INFECTION, 2021, 83 (01) :17-26
[45]   Synergistic activity of antibodies in the multicomponent 4CMenB vaccine [J].
Viviani, Viola ;
Biolchi, Alessia ;
Pizza, Mariagrazia .
EXPERT REVIEW OF VACCINES, 2022, 21 (05) :645-658
[46]   4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents [J].
Biolchi, Alessia ;
Tomei, Sara ;
Brunelli, Brunella ;
Giuliani, Maria ;
Bambini, Stefania ;
Borrow, Ray ;
Claus, Heike ;
Gorla, Maria Cecilia O. ;
Hong, Eva ;
Lemos, Ana Paula S. ;
Lucidarme, Jay ;
Taha, Muhamed-Kheir ;
Vogel, Ulrich ;
Budroni, Sonia ;
Giuliani, Marzia M. ;
Rappuoli, Rino ;
Boucher, Philip ;
Pizza, Mariagrazia .
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (01) :307-316
[47]   Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022 [J].
Rodrigues, C. M. C. ;
MacDonald, L. ;
Ure, R. ;
Smith, A. ;
Cameron, J. C. ;
Maiden, M. C. J. .
MBIO, 2023, 14 (02)
[48]   Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease [J].
Hedari, Carine P. ;
Khinkarly, Rima W. ;
Dbaibo, Ghassan S. .
INFECTION AND DRUG RESISTANCE, 2014, 7 :85-99
[49]   Multicomponent Meningococcal Serogroup B Vaccine (4CMenB; Bexsero®): A Review of its Use in Primary and Booster Vaccination [J].
Carter, Natalie J. .
BIODRUGS, 2013, 27 (03) :263-274
[50]   Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine [J].
Elena Santolaya, Maria ;
O'Ryan, Miguel L. ;
Teresa Valenzuela, Maria ;
Prado, Valeria ;
Vergara, Rodrigo F. ;
Munoz, Alma ;
Toneatto, Daniela ;
Grana, Gabriela ;
Wang, Huajun ;
Dull, Peter M. .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (11) :2304-2310